Dechert Advises Abivax on US$747.5 Million Public Offering on Nasdaq

Dechert advised French biotech company Abivax SA (Euronext Paris: FR0012333284 – ABVX) in connection with its approximately US$747.5 million public offering (equivalent to €637.5 million), consisting of American Depositary Shares (ADSs) listed on the Nasdaq Global Market. This marks a record-breaking transaction for a French biotech. Following the offering and the announcement of Phase 3 clinical trial results for its lead drug candidate, obefazimod, in ulcerative colitis, Abivax’s valuation exceeds €4 billion.

This transaction will enable Abivax to continue the clinical development of its lead drug candidate obefazimod for the treatment of ulcerative colitis and Crohn’s disease.

Dechert, a longstanding advisor to Abivax, has supported this successful biotech through key milestones in its development, including its Nasdaq IPO in 2023, structured financings and fundraising transactions totaling over €1.2 billion, including this public offering. This collaboration underscores Dechert Paris’s commitment to fostering innovation in the life sciences sector and supporting biotech companies like Abivax, their shareholders, and executives in strategic operations benefiting patients.

Abivax was advised on this transaction by partner Alain Decombe and senior associate Vianney Toulouse, with support from associates Mathilde Duchamp and Anaïs Fritzinger.

About Dechert

Dechert is the law firm that helps business leaders lead.

For more than 150 years, we have advised clients on critical issues – from high-stakes litigation to first-in-market transaction structures and complex regulatory matters. Our nearly 1,000 lawyers in commercial centers worldwide are immersed in the key sectors we serve – financial services, private capital, real estate, life sciences and technology.

Dechert delivers unwavering partnership so our clients can achieve unprecedented results.

Dechert’s Paris office is a key component of the firm's strategy in Europe and is active in antitrust/competition and European law, corporate/M&A, financial services & asset management, financing, intellectual property, labor and employment, litigation and compliance, regulatory and tax.

Dechert’s life sciences team in France represents companies ranging from multinational giants to emerging companies involving all aspects of the life sciences industry, including pharmaceuticals, biotechnology, drug discovery, genomics, biopharmaceuticals, diagnostics, medical devices and health care. We also assist investment funds with life sciences investments. Read more »